Details for Patent: 9,630,955
✉ Email this page to a colleague
Which drugs does patent 9,630,955 protect, and when does it expire?
Patent 9,630,955 protects ONGENTYS and is included in one NDA.
This patent has twenty-three patent family members in fifteen countries.
Summary for Patent: 9,630,955
| Title: | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
| Abstract: | There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate. |
| Inventor(s): | Russo; Domenico (S. Mamede do Coronado, PT), Kiss; Laszlo Erno (S. Mamede do Coronado, PT), Wahnon; Jorge Bruno Reis (S. Mamede do Coronado, PT), Learmonth; David Alexander (Alfena, PT), Eszenyi; Tibor (Tiszalok, HU), Zimmermann; Axel (Kirkel-Altstadt, DE), Schlummer; Bjoern (Leverkusen, DE), Kreis; Michael (Leverkusen, DE), Reiter; Klaus (Linz, AT) |
| Assignee: | |
| Application Number: | 14/814,603 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Dosage form; |
Recent additions to Drugs Protected by US Patent 9,630,955
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | ONGENTYS | opicapone | CAPSULE | 212489 | Apr 24, 2020 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | U-3869 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 9,630,955
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-001 | Apr 24, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | METHOD OF TREATING PARKINSON'S DISEASE | ⤷ Try a Trial | ||
| Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-002 | Apr 24, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | METHOD OF TREATING PARKINSON'S DISEASE | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,630,955
International Family Members for US Patent 9,630,955
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 112014014341 | ⤷ Try a Trial | |||
| Canada | 2858025 | ⤷ Try a Trial | |||
| Canada | 3088684 | ⤷ Try a Trial | |||
| Cyprus | 1122580 | ⤷ Try a Trial | |||
| Denmark | 2791134 | ⤷ Try a Trial | |||
| European Patent Office | 2791134 | ⤷ Try a Trial | |||
| European Patent Office | 3604299 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
